Your browser doesn't support javascript.
loading
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.
Garcia-Horton, Alejandro; Cyriac, Sunu L; Gedde-Dahl, Tobias; Floisand, Yngvar; Remberger, Mats; Mattsson, Jonas; Michelis, Fotios V.
Afiliação
  • Garcia-Horton A; Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Cyriac SL; Department of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Gedde-Dahl T; Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Floisand Y; Department of Medical Oncology and Hematology, Amala Institute of Medical Sciences, Thrissur, India.
  • Remberger M; Stem Cell Transplant Unit, Department of Hematology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Mattsson J; Stem Cell Transplantation and Cellular Therapies Programme, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
  • Michelis FV; CanCell - Centre of Cancer Cell Reprogramming, University of Oslo, Oslo, Norway.
Eur J Haematol ; 109(6): 672-679, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36028979
BACKGROUND: Mixed results surround the accuracy of commonly used prognostic risk scores to predict overall survival (OS) and non-relapse mortality (NRM) in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. We hypothesize that a simple prognostic score performs better than conventional scoring systems. PATIENTS AND METHODS: OS risk factors, HCT-CI, age-HCT-CI, and augmented-HCT-CI were studied in 299 patients who underwent allo-HCT for myeloid and lymphoid malignancies. A scoring system was developed based on results and validated in a different cohort of 455 patients. RESULTS: Two-year OS was 51% (95% confidence interval (CI) 0.45-0.56); 2-year NRM was 34% (95% CI 0.29-0.39). HCT-CI and associated scores were grouped into 0-2 and ≥3. Age and HLA mismatch status were the only risk factors to affect OS in multivariate analysis (p = 0.02 and 0.05, respectively). HCT-CI and associated scores were not informative for OS prediction. The weighted scoring system assigned 0 to 2 points for age < 50, 50-64, or ≥65, respectively, and 0-1 points for no HLA mismatch versus any mismatch (except HLA-DQ). Distinct 2-year OS (62%, 53%, and 38% [p = <0.001]) and NRM (24%, 34%, and 43% [p = 0.02]) groups were characterized. The scoring system was validated in a second independent cohort with similar results on OS and NRM (p < 0.001). CONCLUSIONS: A simple scoring system based on recipient's age and mismatch status accurately predict OS and NRM in two distinct cohorts of allo-HCT patients. Its simplicity makes it a helpful tool to aid clinicians and patients in clinical decision-making.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article